ArticleBJUI compass2026
1H MR-based detection of human plasma metabolic alterations in clear cell renal cell carcinoma.
Article in BJUI compass, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- 1H MR-based detection of human plasma metabolic alterations in clear cell renal cell carcinoma.BJUI compass · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Objectives: This study aimed to evaluate the potential of plasma-based proton magnetic resonance spectroscopy (1H-MRS) for non-invasive discrimination between clear cell renal cell carcinoma (ccRCC), benign renal masses (angiomyolipoma and oncocytoma) and healthy controls by identifying disease-specific metabolic signatures. Patients and Methods: We performed 1H-MRS metabolic profiling of human plasma samples from 30 individuals divided into three cohorts: ccRCC ( Results: We observed altered metabolic plasma profiles in ccRCC patients compared to normal controls and benign patients. We detected significantly increased concentrations of hydroxybutyrate (normal vs. ccRCC, Conclusion: This pilot study demonstrates that plasma 1H-MRS can detect metabolic alterations associated with ccRCC and benign renal masses. These findings support the feasibility of using metabolomic profiling as a non-invasive diagnostic tool for renal mass characterization. Larger validation studies are warranted to confirm diagnostic accuracy and explore utility in clinical decision-making.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.